

Jose-Antonio Perez-Simon

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8912309/jose-antonio-perez-simon-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57
papers

1,241
citations

19
h-index

34
g-index

63
ext. papers

1,491
ext. citations

4.6
avg, IF

4.06
L-index

#	Paper	IF	Citations
57	Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. <i>Blood</i> , 2006 , 107, 3575-83	2.2	180
56	Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. <i>Haematologica</i> , 2011 , 96, 1072-6	6.6	141
55	Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. <i>Blood</i> , 2003 , 102, 1108-13	2.2	95
54	Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. <i>British Journal of Haematology</i> , 2005 , 130, 394-403	4.5	95
53	Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. <i>British Journal of Haematology</i> , 2003 , 121, 104-8	4.5	77
52	Vitamin D: Effect on Haematopoiesis and Immune System and Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	69
51	Chronic graft-versus-host disease: Pathogenesis and clinical management. <i>Drugs</i> , 2006 , 66, 1041-57	12.1	59
50	Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. <i>Haematologica</i> , 2009 , 94, 975-83	6.6	45
49	Dual cholinergic signals regulate daily migration of hematopoietic stem cells and leukocytes. <i>Blood</i> , 2019 , 133, 224-236	2.2	40
48	Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. <i>Bone Marrow Transplantation</i> , 2020 , 55, 641-648	4.4	35
47	Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, 80-6	2	34
46	Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. <i>British Journal of Haematology</i> , 2013 , 162, 474-82	4.5	32
45	Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial. <i>Clinical Cancer Research</i> , 2016 , 22, 5673-5681	12.9	32
44	Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. <i>Leukemia</i> , 2021 , 35, 201-214	10.7	29
43	Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma. <i>Hematological Oncology</i> , 2015 , 33, 151-8	1.3	27
42	Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. <i>Haematologica</i> , 2015 , 100, 1294-300	6.6	23
41	Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1050-1058	4.4	23

40	Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 236-44	2	19
39	First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4260-4273	2.2	19
38	Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1808-1815	4.7	18
37	The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation. <i>Haematologica</i> , 2012 , 97, 1329-37	6.6	14
36	Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions. <i>Blood Reviews</i> , 2021 , 48, 100792	11.1	14
35	Noninvasive prenatal diagnosis by cell-free DNA screening for fetomaternal HPA-1a platelet incompatibility. <i>Transfusion</i> , 2018 , 58, 2272-2279	2.9	13
34	Evaluation of prognostic factors among patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2012 , 97, 1187-95	6.6	10
33	A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. <i>Leukemia Research</i> , 2019 , 76, 1-10	2.7	9
32	Intermediate doses of cytarabine plus granulocyte-colony-stimulating factor as an effective and safe regimen for hematopoietic stem cell collection in lymphoma patients with prior mobilization failure. <i>Transfusion</i> , 2015 , 55, 875-9	2.9	8
31	Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. <i>Annals of Hematology</i> , 2021 , 100, 1181-1194	3	8
30	Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?. <i>Leukemia</i> , 2021 , 35, 1571-1585	10.7	7
29	The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1893-1902	1.9	6
28	Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms. <i>Clinical Cancer Research</i> , 2019 , 25, 4616-4623	12.9	6
27	Evaluation of a method for murine monocyte isolation by bone marrow depletion. <i>Analytical Biochemistry</i> , 2015 , 480, 42-8	3.1	5
26	ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype. <i>Cancer Medicine</i> , 2020 , 9, 3637-3646	4.8	5
25	PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation. <i>Annals of Hematology</i> , 2018 , 97, 2217-2224	3	5
24	Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project. <i>Haematologica</i> , 2021 , 106, 3079-3089	6.6	5
23	Selection of Tumor-Specific Cytotoxic T Lymphocytes in Acute Myeloid Leukemia Patients Through the Identification of T-Cells Capable to Establish Stable Interactions With the Leukemic Cells: "Doublet Technology". <i>Frontiers in Immunology</i> , 2018 , 9, 1971	8.4	5

22	Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 1001-1014	7.4	4
21	Genotoxicity of tetrahydrofolic acid to hematopoietic stem and progenitor cells. <i>Cell Death and Differentiation</i> , 2018 , 25, 1967-1979	12.7	4
20	Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 2042-2047	4.7	4
19	Cholinergic signals preserve haematopoietic stem cell quiescence during regenerative haematopoiesis.. <i>Nature Communications</i> , 2022 , 13, 543	17.4	4
18	ATRA Augments BCMA Expression on Myeloma Cells and Enhances Recognition By BCMA-CAR T-Cells. <i>Blood</i> , 2020 , 136, 13-14	2.2	3
17	Intravascular lymphoma: look through the small vessels. <i>Annals of Hematology</i> , 2017 , 96, 517-519	3	2
16	An active isodicentric x chromosome in a case of refractory anaemia with ring sideroblasts associated with marked thrombocytosis. <i>Case Reports in Genetics</i> , 2014 , 2014, 205318	0.7	2
15	Pre-Clinical Trial to Evaluate the Efficacy of Delayed Administration of Ixazomib in the Prophylaxis of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2018 , 132, 4521-4521	2.2	2
14	Candida parapsilosis misleading the automated absolute and differential white blood cell count. <i>Annals of Hematology</i> , 2017 , 96, 169-170	3	1
13	Phase II trial of allogeneic transplantation plus novel drugs in multiple myeloma: effect of intensifying reduced intensity conditioning with bortezomib and adding maintenance treatment.. <i>Transplantation and Cellular Therapy</i> , 2022 ,		1
12	Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021 , 56, 3049-3058	4.4	1
11	MUFAs in High-Fat Diets Protect against Obesity-Induced Bias of Hematopoietic Cell Lineages. <i>Molecular Nutrition and Food Research</i> , 2021 , 65, e2001203	5.9	0
10	Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.. <i>Leukemia Research</i> , 2022 , 115, 106821	2.7	0
9	Effect of Vitamin D on Graft-Versus-Host Disease. <i>Biomedicines</i> , 2022 , 10, 987	4.8	0
8	Effect of Mesenchymal Stem Cells on the Viability, Proliferation and Differentiation of B Lymphocytes.. <i>Blood</i> , 2007 , 110, 3880-3880	2.2	
7	Prognostic Impact of Adverse Karyotype and Treatment in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 5241-5241	2.2	
6	Pronostic Value of Pretransplant Echocardiography in Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015 , 126, 4363-4363	2.2	
5	An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015 , 126, 3142-3142	2.2	

- 4 Low-Dose Dexamethasone Does Not Abrogate the Immunomodulatory Effects of Lenalidomide and Both Reactivate the Impaired Immune System of High-Risk Smoldering Multiple Myeloma Patients. *Blood*, **2015**, 126, 2955-2955 2.2
- 3 The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma. *Blood*, **2015**, 126, 2007-2007^{2,2}
- 2 Results of Allogeneic Transplantation As First Line Rescue Therapy in Patients with Multiple Myeloma Relapsing to a Prior Autograft: Role of Conditioning Regimen. *Blood*, **2015**, 126, 4373-4373 2.2
- 1 Clinical Outcome, Molecular and Gene Expression Analysis of 20 MLL-Rearranged AML from a Single Institution. *Blood*, **2015**, 126, 4943-4943 2.2